Acuta Capital Partners’s Praxis Precision Medicines PRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding PRAX
BBA
Acuta Capital Partners's PRAX Position: Q3 2026 in Review
Acuta Capital Partners increased its Praxis Precision Medicines (PRAX) stake by 1.7% in Q3 2026, buying an estimated $462K and bringing the position to 84,193 shares worth $24.5M. The position accounts for 18.63% of the portfolio, ranked #1.
Acuta Capital Partners first reported a position in PRAX in Q4 2020 and has held it in 16 quarters since. The position peaked at $27.7M in Q2 2026. 338 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.
- Acuta Capital Partners held 84,193 shares of Praxis Precision Medicines worth $24.5M as of Q3 2026.
- Acuta Capital Partners bought 1,397 Praxis Precision Medicines shares in Q3 2026, an estimated $462K.
- Praxis Precision Medicines made up 18.63% of Acuta Capital Partners's portfolio in Q3 2026, its #1 holding.
- Acuta Capital Partners first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 16 quarters since.
- Acuta Capital Partners's Praxis Precision Medicines position peaked at $27.7M in Q2 2026.
- 338 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.
Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.